Duke Royalty: a princely return for income investors
Britain’s only listed royalty-finance company chooses its clientele wisely, making it a compelling income play
With interest rates well below inflation, it is difficult to find deposit accounts offering over 0.4%. I have therefore previously highlighted several large, stable companies with modest dividend yields just above deposit-account returns, but with reasonable growth prospects. This month I am recommending a smaller company with a unique business model that enables it to offer a much higher yield with moderate risk.
The company is Duke Royalty (Aim: DUKE), which lends companies money in return for a royalty on future sales. It provides finance at a lower cost than private equity and does not take control away from the owners, as private-equity lenders do.
Duke typically offers between £5m and £20m and can give a decision on making the money available in about eight weeks. The royalty agreement can be likened to a corporate mortgage where both principal and royalty are paid back over a period of 25 to 40 years. The initial yield on Duke’s investment is 12%-14% of capital provided and the royalty rate is reset upwards or downwards each year (between a 6% increase and a 6% fall, depending on the client’s sales performance), so Duke participates consistently in a client’s growth. The company can buy back the royalty after three years by paying the initial principal along with a 20% redemption premium.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Royalty finance
Royalty finance is well established in North America, where it is a $50bn sector, and Duke has brought the idea to the UK and Europe. Duke is the only listed UK royalty company, having taken over its only British competitor, Capital Step, in 2019. Typical clients are well-established, profitable, owner-managed medium-sized businesses wishing to expand by acquisition, buy out a minority shareholder, or finance a management buyout from a larger company.
Duke tempers the risk in its investments by stipulating that royalty payments should be worth significantly less than 50% of a company’s cash flow. Duke seeks firms with a sustainable competitive advantage. It avoids start-ups, oil and gas, mining and biotech companies, and aims to diversify by industry and geography. Two of Duke’s typical client companies are United Glass Group (UGG) and Brightwater Selection. UGG is one of the UK’s leading glass merchants and processors. Duke provided it with funding of £6.5m in April 2018, which allowed it to refinance existing debt and buy out a minority equity stake in a key subsidiary. A second investment of £4.5m facilitated the acquisition of London Architectural Glass and purchase of a key facility’s freehold.
Brightwater Selection, a recruitment company, was a management buyout funded with £1.9m from Duke. A further £7.7m was provided to Brightwater in January 2020 to acquire PE Global, a leading healthcare and life sciences recruiter in Ireland. Duke’s results for the year to the end of March 2020, the last before the virus, show that it had 12 royalty partners (clients) and made substantial follow-on investments in three of them, so that £20.4m of new capital was deployed during the year.
To finance expansion, it raised new equity of £17.5m and refinanced a revolving credit facility on better terms; the facility was also increased to £30m. Cash revenue for the year was £10.4m, up by 91%, with net cash inflow from operating activities £6.8m, up by 65%, and total dividends for the year 2.95p per share, up by 5%. Given the uncertainties in 2020 about the effects of Covid-19, Duke wisely preserved cash by paying the first two quarterly dividends of 2020/2021 as scrip dividends of 0.5p.
Still, the positive trading update for the third quarter of 202/2021 said the cash position had improved, so a cash dividend of 0.5p was paid. The results for the year to the end of March 2021 showed operating net cash flow up to £8.94m from £6.78m in 2020 and £4.11m in 2019. The 2020/2021 results encompassed the virus period and demonstrated the resilience of Duke’s royalty model.
A juicy and growing dividend
Duke’s costs are fixed so increases in revenue work straight through to the bottom line. It is therefore encouraging that 2021 has so far seen five new royalty deals, including a £6.2m investment in Fabrikat (a well-established steel fabricator), and a new €10m agreement in June with Fairmed Healthcare Group of Switzerland .
There were more deals in July, August and September. Further investments have been made into existing partners, such as £6.5m in UGG to fund another acquisition. The first royalty partner in North America has been secured. Three exits so far in 2021 have raised £18m. Duke has liquidity of more than £55m to fund its growing pipeline of opportunities.
In assessing Duke as an investment, the key issue is whether the dividend can increase. This is determined by the number of new royalty partners and whether partners are well chosen and can grow their businesses to increase royalty payments. The virus in 2020 provided a stiff test of clients’ quality and it is reassuring that the key measure of operating cash flow per share has increased from 2019 to 2020 and then again, to 3.68p per share, in 2021. This gives investors confidence in Duke’s prospects. Its shares cost 50p in late 2019, fell to 19p and are now around 43p. Dividends of 2.25p were paid in 2020-2021, giving a trailing yield of 5.3%. The annual dividend yield has ranged from 5% to 8% since flotation in 2017.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Highly qualified (BSc PhD CPhys FInstP MIoD) expert in R&D management, business improvement and investment analysis, Dr Mike Tubbs worked for decades on the 'inside' of corporate giants such as Xerox, Battelle and Lucas. Working in the research and development departments, he learnt what became the key to his investing; knowledge which gave him a unique perspective on the stock markets.
Dr Tubbs went on to create the R&D Scorecard which was presented annually to the Department of Trade & Industry and the European Commission. It was a guide for European businesses on how to improve prospects using correctly applied research and development. He has been a contributor to MoneyWeek for many years, with a particular focus on R&D-driven growth companies.
-
How to invest in nuclear power
We need nuclear power to go green, says Dominic Frisby. But there is a better option than huge power stations
By Dominic Frisby Published
-
Chase slashes its easy-access savings rate – is it time to switch?
The Chase easy-access savings account has proved popular with savers thanks to its competitive rate and bonus deals. But, as the rate has dropped, has it lost its charm?
By Katie Williams Published
-
Pfizer shares rise as US investor takes $1 billion stake
Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic options appear limited
By Dr Matthew Partridge Published
-
LSL Property Services: a profit-machine in the property sector
LSL covers every area of the residential real estate market and should thrive after its shake-up
By Rupert Hargreaves Published
-
Global car shares slide amid lower demand in China – what happens now?
Has the car sector run into trouble? Britain’s Aston Martin and Germany’s Volkswagen are among the key automobile brands that have issued profit warnings.
By Alex Rankine Published
-
Qualcomm could acquire rival Intel – but securing the deal won't be easy
A tie-up between Qualcomm and its semiconductor rival Intel would be a coup. But multiple regulatory and commercial hurdles lie ahead.
By Dr Matthew Partridge Published
-
How to invest in the quiet market months
Here's how to invest in the quiet market months, since “sell in May” hasn’t paid off this year.
By Cris Sholto Heaton Published
-
Spire Healthcare: invest in the booming demand for private healthcare
Spire Healthcare is one of the few listed companies benefiting from the growing trend in private healthcare. Should you invest?
By Rupert Hargreaves Published
-
Are insurance companies a good investment?
Costs may be soaring but the insurance sector is currently going through one of its most profitable periods. The market has been slow to realise the opportunity here
By Rupert Hargreaves Published
-
Google's legal challenges – could it be broken up?
Google is fending off legal challenges from both the EU and the US. But would breaking it up actually work?
By Dr Matthew Partridge Published